Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs

• Published in: Hematology reports Vol. 10; no. 1; p. 7523
• Main Authors: Mancuso, Salvatrice, Sucato, Giuseppe, Carlisi, Melania, Santoro, Marco, Tarantino, Giuseppe, Iannitto, Emilio, Napolitano, Mariasanta, Siragusa, Sergio
• Format: Journal Article
• Language: English
• Published: Italy MDPI AG 29-03-2018; PAGEPress Scientific Publications, Pavia, Italy; PAGEPress Publications, Pavia, Italy
• Subjects: Bone marrow; Case Report; CD59 antigen; Complement regulatory proteins; Diagnosis; Hemolytic anemia; paroxysmal nocturnal hemoglo-binuria, thrombotic events, renal failure, Eculizumab; Paroxysmal nocturnal hemoglobinuria; Patients; Thrombosis; Eculizumab; renal failure; paroxysmal nocturnal hemoglobinuria; thrombotic events
• ISSN: 2038-8322; 2038-8330
• DOI: 10.4081/hr.2018.7523

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disorder characterized by hemolytic anemia, bone marrow failure and thrombosis, caused by a somatic mutation in PIG-A gene that results in the absence of CD55 and CD59, two important complement regulatory proteins. In this paper, a case of PNH is retrospectively examined looking for clinical and laboratory features, and the entire course of the disease from the onset of the symptoms is described, together with an adequate follow- up over a 7-years treatment period. In this case, the not specificity and the limited clinical relevance of the symptoms led to a delay in diagnosis. After thrombosis, Eculizumab therapy has been shown to be effective, and during seven years of followup no events have occurred that put the patient's life at risk. A multidisciplinary approach is crucial in cases like this, in order to allow early diagnosis and minimize the risks for the patients.